Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline characteristics

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies

 

Study CHN

Study AUS

 

Part 1

Part 2

 
 

Placebo (n = 10)

SHR-1707 (n = 40)

Placebo

(n = 4)

SHR-1707 (n = 8)

Placebo

(n = 6)

SHR-1707 (n = 24)

Mean age (SD), years

26.2 (6.1)

27.2 (5.9)

56.8 (1.7)

57.4 (2.8)

23.5 (8.5)

26.8 (6.9)

Male, n (%)

8 (80.0)

31 (77.5)

2 (50.0)

4 (50.0)

1 (16.7)

8 (33.3)

Race, n (%)

      

Asian

10 (100.0)

40 (100.0)

4 (100.0)

8 (100.0)

1 (16.7)

1 (4.2)

White

0

0

0

0

4 (66.7)

23 (95.8)

Other

0

0

0

0

1 (16.7)

0

Mean weight (SD), kg

64.7 (7.3)

66.1 (10.3)

63.4 (2.5)

61.8 (6.7)

68.9 (12.4)

72.9 (10.7)

Mean BMI (SD), kg/m2

21.9 (2.5)

23.1 (2.7)

24.6 (2.4)

23.1 (2.5)

22.7 (3.5)

24.5 (3.2)

  1. BMI, body mass index; SD, standard deviation
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193